1. Home
  2. NUVL vs TX Comparison

NUVL vs TX Comparison

Compare NUVL & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$99.24

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Logo Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

TX

Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

HOLD

Current Price

$39.05

Market Cap

8.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
TX
Founded
2017
1961
Country
United States
Luxembourg
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Steel/Iron Ore
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
8.5B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
NUVL
TX
Price
$99.24
$39.05
Analyst Decision
Strong Buy
Buy
Analyst Count
15
6
Target Price
$135.33
$36.92
AVG Volume (30 Days)
443.1K
254.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
6.73%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$13.25
Revenue Next Year
$1,064.25
$6.86
P/E Ratio
N/A
$20.15
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$24.00
52 Week High
$113.02
$45.57

Technical Indicators

Market Signals
Indicator
NUVL
TX
Relative Strength Index (RSI) 42.84 29.19
Support Level $98.65 $37.08
Resistance Level $107.13 $45.57
Average True Range (ATR) 4.05 1.29
MACD -0.31 -0.58
Stochastic Oscillator 19.28 6.76

Price Performance

Historical Comparison
NUVL
TX

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About TX Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.

Share on Social Networks: